| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| GA-Binding Protein Transcription Factor | 13 | 2016 | 16 | 1.890 |
Why?
|
| DNA-Binding Proteins | 13 | 2011 | 1226 | 1.090 |
Why?
|
| Transcription Factors | 16 | 2014 | 1561 | 1.050 |
Why?
|
| Myelopoiesis | 3 | 2011 | 13 | 0.830 |
Why?
|
| Promoter Regions, Genetic | 15 | 2007 | 689 | 0.810 |
Why?
|
| CD18 Antigens | 7 | 2006 | 30 | 0.760 |
Why?
|
| Proto-Oncogene Proteins | 7 | 2016 | 344 | 0.760 |
Why?
|
| Myeloid Cells | 5 | 2008 | 98 | 0.710 |
Why?
|
| Tretinoin | 3 | 2008 | 49 | 0.690 |
Why?
|
| Sp1 Transcription Factor | 6 | 2004 | 21 | 0.660 |
Why?
|
| Trans-Activators | 4 | 2016 | 321 | 0.580 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 3 | 2013 | 70 | 0.450 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2014 | 193 | 0.430 |
Why?
|
| Monocytes | 3 | 2012 | 362 | 0.430 |
Why?
|
| Precision Medicine | 1 | 2014 | 134 | 0.380 |
Why?
|
| CD11c Antigen | 1 | 2012 | 8 | 0.380 |
Why?
|
| Gene Expression Regulation | 9 | 2016 | 1635 | 0.380 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2014 | 378 | 0.370 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2012 | 74 | 0.370 |
Why?
|
| Transcription, Genetic | 7 | 2005 | 910 | 0.360 |
Why?
|
| Leukocytosis | 1 | 2012 | 15 | 0.360 |
Why?
|
| Protein Kinases | 1 | 2013 | 154 | 0.350 |
Why?
|
| Cell Differentiation | 6 | 2016 | 1391 | 0.320 |
Why?
|
| Mitochondria | 1 | 2014 | 416 | 0.320 |
Why?
|
| Receptors, Retinoic Acid | 3 | 2008 | 55 | 0.310 |
Why?
|
| Dendritic Cells | 1 | 2012 | 534 | 0.300 |
Why?
|
| Membrane Proteins | 3 | 2012 | 926 | 0.300 |
Why?
|
| Cell Cycle | 2 | 2013 | 398 | 0.300 |
Why?
|
| E1A-Associated p300 Protein | 1 | 2006 | 9 | 0.240 |
Why?
|
| Mice | 12 | 2016 | 11185 | 0.230 |
Why?
|
| Animals | 18 | 2016 | 21489 | 0.230 |
Why?
|
| Leukemia | 1 | 2005 | 62 | 0.210 |
Why?
|
| Base Sequence | 12 | 2000 | 1332 | 0.210 |
Why?
|
| Hematopoiesis | 1 | 2004 | 128 | 0.200 |
Why?
|
| Chromatin | 2 | 2008 | 643 | 0.190 |
Why?
|
| Cell Line | 8 | 2007 | 2031 | 0.190 |
Why?
|
| Binding Sites | 7 | 2006 | 921 | 0.180 |
Why?
|
| Cells, Cultured | 6 | 2014 | 2194 | 0.180 |
Why?
|
| Chromatin Immunoprecipitation | 3 | 2016 | 146 | 0.170 |
Why?
|
| Hematopoietic Stem Cells | 3 | 2016 | 304 | 0.170 |
Why?
|
| Leukocyte Elastase | 2 | 1999 | 13 | 0.170 |
Why?
|
| Granulocytes | 3 | 2016 | 73 | 0.160 |
Why?
|
| Transcriptional Activation | 4 | 2006 | 196 | 0.160 |
Why?
|
| Radiation-Sensitizing Agents | 2 | 1997 | 16 | 0.160 |
Why?
|
| Heart Neoplasms | 1 | 2000 | 36 | 0.150 |
Why?
|
| Lymphoma, B-Cell | 1 | 2000 | 63 | 0.150 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 1997 | 44 | 0.150 |
Why?
|
| Neoplastic Stem Cells | 2 | 2012 | 196 | 0.150 |
Why?
|
| Pseudogenes | 1 | 1999 | 12 | 0.150 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2016 | 466 | 0.150 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 1999 | 33 | 0.150 |
Why?
|
| Paclitaxel | 2 | 1997 | 102 | 0.150 |
Why?
|
| Monoclonal Gammopathy of Undetermined Significance | 1 | 2019 | 35 | 0.150 |
Why?
|
| Humans | 28 | 2019 | 65826 | 0.140 |
Why?
|
| Mice, Knockout | 3 | 2014 | 2168 | 0.140 |
Why?
|
| Fibroblasts | 2 | 2014 | 423 | 0.140 |
Why?
|
| Nuclear Proteins | 3 | 2000 | 792 | 0.140 |
Why?
|
| Transfection | 6 | 2007 | 700 | 0.140 |
Why?
|
| Molecular Sequence Data | 9 | 2000 | 1980 | 0.140 |
Why?
|
| Immunoblotting | 3 | 2016 | 202 | 0.130 |
Why?
|
| Gene Expression | 3 | 2013 | 855 | 0.130 |
Why?
|
| Mice, Transgenic | 2 | 2013 | 1291 | 0.120 |
Why?
|
| Mutagenesis | 1 | 1997 | 133 | 0.120 |
Why?
|
| Genes, p53 | 1 | 1996 | 51 | 0.120 |
Why?
|
| DNA | 4 | 1999 | 853 | 0.120 |
Why?
|
| Survival Rate | 2 | 2016 | 847 | 0.120 |
Why?
|
| Electronic Health Records | 1 | 2019 | 398 | 0.120 |
Why?
|
| Leukocytes | 2 | 2012 | 110 | 0.120 |
Why?
|
| Polymerase Chain Reaction | 2 | 2012 | 514 | 0.110 |
Why?
|
| Gene Expression Regulation, Leukemic | 2 | 2012 | 52 | 0.110 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2016 | 151 | 0.110 |
Why?
|
| Burkitt Lymphoma | 1 | 2016 | 74 | 0.110 |
Why?
|
| Neoplasm Proteins | 2 | 2012 | 286 | 0.110 |
Why?
|
| Genes, Mitochondrial | 1 | 2014 | 5 | 0.110 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2014 | 31 | 0.110 |
Why?
|
| Multiple Myeloma | 1 | 2019 | 375 | 0.100 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 1996 | 186 | 0.100 |
Why?
|
| Antigens, CD | 2 | 1992 | 344 | 0.100 |
Why?
|
| RNA, Ribosomal | 1 | 2014 | 60 | 0.100 |
Why?
|
| Algorithms | 1 | 2019 | 1060 | 0.100 |
Why?
|
| RNA, Untranslated | 1 | 2014 | 105 | 0.100 |
Why?
|
| Oxygen Consumption | 1 | 2014 | 213 | 0.100 |
Why?
|
| Flow Cytometry | 2 | 2012 | 664 | 0.100 |
Why?
|
| Deoxycytidine | 2 | 2011 | 45 | 0.100 |
Why?
|
| Protein Binding | 5 | 2004 | 1637 | 0.100 |
Why?
|
| Imatinib Mesylate | 1 | 2013 | 34 | 0.100 |
Why?
|
| Mutation | 3 | 2012 | 2674 | 0.100 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2012 | 24 | 0.090 |
Why?
|
| Benzamides | 1 | 2013 | 69 | 0.090 |
Why?
|
| Apoptosis | 2 | 2014 | 1100 | 0.090 |
Why?
|
| Adenosine Triphosphate | 1 | 2014 | 301 | 0.090 |
Why?
|
| Receptors, Leukocyte-Adhesion | 1 | 1992 | 3 | 0.090 |
Why?
|
| Piperazines | 1 | 2013 | 86 | 0.090 |
Why?
|
| Signal Transduction | 5 | 2016 | 3168 | 0.090 |
Why?
|
| Tumor Cells, Cultured | 4 | 2003 | 426 | 0.090 |
Why?
|
| DNA Methylation | 1 | 2014 | 306 | 0.090 |
Why?
|
| Leukemia, Promyelocytic, Acute | 2 | 2008 | 17 | 0.090 |
Why?
|
| Enhancer Elements, Genetic | 2 | 2006 | 119 | 0.090 |
Why?
|
| Pyrimidines | 1 | 2013 | 144 | 0.090 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2008 | 269 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-ets | 4 | 2002 | 19 | 0.090 |
Why?
|
| Precursor Cells, T-Lymphoid | 1 | 2011 | 1 | 0.090 |
Why?
|
| Antigens, CD20 | 1 | 2011 | 13 | 0.090 |
Why?
|
| DNA Probes | 3 | 1998 | 34 | 0.090 |
Why?
|
| Precursor Cells, B-Lymphoid | 1 | 2011 | 8 | 0.090 |
Why?
|
| CD11b Antigen | 1 | 2011 | 19 | 0.090 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2013 | 198 | 0.090 |
Why?
|
| Epigenesis, Genetic | 1 | 2014 | 408 | 0.080 |
Why?
|
| Histones | 1 | 2014 | 497 | 0.080 |
Why?
|
| Gene Knockout Techniques | 1 | 2011 | 97 | 0.080 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2011 | 54 | 0.080 |
Why?
|
| Bone Marrow Cells | 1 | 2011 | 237 | 0.080 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2009 | 205 | 0.080 |
Why?
|
| Doxorubicin | 3 | 2011 | 98 | 0.080 |
Why?
|
| Sarcoma, Kaposi | 1 | 2010 | 17 | 0.080 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2010 | 42 | 0.080 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2005 | 588 | 0.080 |
Why?
|
| Lung Neoplasms | 1 | 1996 | 712 | 0.080 |
Why?
|
| Cytoskeletal Proteins | 2 | 2002 | 204 | 0.070 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2010 | 129 | 0.070 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2009 | 89 | 0.070 |
Why?
|
| Mutagenesis, Site-Directed | 3 | 2016 | 252 | 0.070 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 3 | 2016 | 28 | 0.070 |
Why?
|
| Precipitin Tests | 2 | 2006 | 77 | 0.070 |
Why?
|
| Antigens, Differentiation | 1 | 1989 | 144 | 0.070 |
Why?
|
| Cell Nucleus | 4 | 2016 | 634 | 0.070 |
Why?
|
| Peroxidase | 1 | 1989 | 70 | 0.070 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2009 | 210 | 0.070 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2012 | 679 | 0.070 |
Why?
|
| Retinoids | 1 | 2008 | 11 | 0.070 |
Why?
|
| Leukemia, Myeloid | 1 | 2008 | 35 | 0.070 |
Why?
|
| Myeloproliferative Disorders | 1 | 2008 | 15 | 0.070 |
Why?
|
| DNA Primers | 2 | 1999 | 302 | 0.070 |
Why?
|
| Antineoplastic Agents | 1 | 2013 | 645 | 0.070 |
Why?
|
| Phenotype | 1 | 2011 | 1236 | 0.060 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2008 | 64 | 0.060 |
Why?
|
| DNA Polymerase I | 1 | 2007 | 5 | 0.060 |
Why?
|
| Thymidylate Synthase | 1 | 2007 | 6 | 0.060 |
Why?
|
| S-Phase Kinase-Associated Proteins | 1 | 2007 | 7 | 0.060 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2007 | 32 | 0.060 |
Why?
|
| Cyclins | 1 | 2007 | 41 | 0.060 |
Why?
|
| NIH 3T3 Cells | 1 | 2007 | 99 | 0.060 |
Why?
|
| Mice, Inbred Strains | 1 | 2007 | 185 | 0.060 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2007 | 58 | 0.060 |
Why?
|
| Integrases | 1 | 2007 | 41 | 0.060 |
Why?
|
| Vincristine | 2 | 2011 | 26 | 0.060 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2007 | 52 | 0.060 |
Why?
|
| Cell Proliferation | 2 | 2009 | 1044 | 0.060 |
Why?
|
| U937 Cells | 1 | 2006 | 10 | 0.060 |
Why?
|
| Retinoid X Receptors | 1 | 2006 | 10 | 0.060 |
Why?
|
| Cyclophosphamide | 2 | 2011 | 84 | 0.060 |
Why?
|
| Prednisone | 2 | 2011 | 83 | 0.060 |
Why?
|
| Combined Modality Therapy | 3 | 2012 | 375 | 0.060 |
Why?
|
| Retroviridae Proteins, Oncogenic | 2 | 1995 | 3 | 0.060 |
Why?
|
| Cloning, Molecular | 2 | 1999 | 386 | 0.060 |
Why?
|
| Models, Genetic | 1 | 2006 | 267 | 0.050 |
Why?
|
| Neoplasm Staging | 2 | 2016 | 553 | 0.050 |
Why?
|
| Middle Aged | 7 | 2019 | 18491 | 0.050 |
Why?
|
| Protein Structure, Tertiary | 1 | 2006 | 672 | 0.050 |
Why?
|
| Sp3 Transcription Factor | 1 | 2004 | 2 | 0.050 |
Why?
|
| Tetradecanoylphorbol Acetate | 2 | 1995 | 62 | 0.050 |
Why?
|
| Protein Biosynthesis | 2 | 1999 | 333 | 0.050 |
Why?
|
| Kenya | 2 | 2016 | 98 | 0.050 |
Why?
|
| Receptor Cross-Talk | 1 | 2003 | 10 | 0.050 |
Why?
|
| Response Elements | 1 | 2003 | 41 | 0.050 |
Why?
|
| Oncogene Proteins | 1 | 2002 | 34 | 0.050 |
Why?
|
| Models, Biological | 1 | 2007 | 1193 | 0.040 |
Why?
|
| Cell Line, Tumor | 1 | 2006 | 1573 | 0.040 |
Why?
|
| Muscular Dystrophy, Duchenne | 1 | 2002 | 46 | 0.040 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 2002 | 98 | 0.040 |
Why?
|
| Electrophoretic Mobility Shift Assay | 2 | 2016 | 61 | 0.040 |
Why?
|
| Treatment Failure | 2 | 2012 | 208 | 0.040 |
Why?
|
| Disease Progression | 2 | 2019 | 1229 | 0.040 |
Why?
|
| Male | 6 | 2019 | 31398 | 0.040 |
Why?
|
| Lactoferrin | 1 | 2000 | 37 | 0.040 |
Why?
|
| Remission Induction | 2 | 1997 | 149 | 0.040 |
Why?
|
| Dyspnea | 1 | 2000 | 120 | 0.040 |
Why?
|
| Nerve Growth Factors | 1 | 1999 | 28 | 0.040 |
Why?
|
| Chromosome Mapping | 1 | 1999 | 297 | 0.030 |
Why?
|
| Serine Endopeptidases | 1 | 1999 | 125 | 0.030 |
Why?
|
| Aged, 80 and over | 3 | 2019 | 5681 | 0.030 |
Why?
|
| Glycoproteins | 1 | 1999 | 189 | 0.030 |
Why?
|
| Enzyme Induction | 1 | 1997 | 25 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-myb | 1 | 1997 | 12 | 0.030 |
Why?
|
| Casein Kinase II | 1 | 1997 | 16 | 0.030 |
Why?
|
| Deoxyribonuclease HindIII | 1 | 1997 | 1 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2000 | 995 | 0.030 |
Why?
|
| Deoxyribonucleases, Type II Site-Specific | 1 | 1997 | 21 | 0.030 |
Why?
|
| Aged | 4 | 2019 | 15141 | 0.030 |
Why?
|
| Dimerization | 1 | 1997 | 145 | 0.030 |
Why?
|
| Multigene Family | 1 | 1997 | 106 | 0.030 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1997 | 185 | 0.030 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 1996 | 16 | 0.030 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 1997 | 67 | 0.030 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 1997 | 103 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 1117 | 0.030 |
Why?
|
| Female | 5 | 2019 | 34414 | 0.030 |
Why?
|
| Stomach Neoplasms | 1 | 1997 | 81 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 2 | 2016 | 3504 | 0.030 |
Why?
|
| DNA Footprinting | 1 | 1995 | 18 | 0.030 |
Why?
|
| Binding, Competitive | 1 | 1995 | 96 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 1995 | 34 | 0.030 |
Why?
|
| Exons | 1 | 1996 | 208 | 0.030 |
Why?
|
| Forecasting | 1 | 1996 | 231 | 0.030 |
Why?
|
| Calcitriol | 1 | 1995 | 25 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2016 | 211 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2016 | 180 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 420 | 0.030 |
Why?
|
| Cell Death | 1 | 1996 | 289 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2016 | 210 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 1996 | 417 | 0.030 |
Why?
|
| Phosphorylation | 1 | 1997 | 963 | 0.030 |
Why?
|
| Biopsy | 1 | 2016 | 463 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2016 | 617 | 0.030 |
Why?
|
| Massachusetts | 1 | 2019 | 2158 | 0.020 |
Why?
|
| Pancreatic Neoplasms | 1 | 1997 | 354 | 0.020 |
Why?
|
| Drosophila melanogaster | 1 | 1998 | 563 | 0.020 |
Why?
|
| CD11 Antigens | 2 | 1992 | 16 | 0.020 |
Why?
|
| Tandem Repeat Sequences | 1 | 2012 | 25 | 0.020 |
Why?
|
| Cytarabine | 1 | 2012 | 36 | 0.020 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2012 | 26 | 0.020 |
Why?
|
| Gene Duplication | 1 | 2012 | 35 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2011 | 859 | 0.020 |
Why?
|
| Genomic Library | 1 | 1992 | 10 | 0.020 |
Why?
|
| Restriction Mapping | 1 | 1992 | 49 | 0.020 |
Why?
|
| RNA, Neoplasm | 1 | 1992 | 36 | 0.020 |
Why?
|
| Megakaryocytes | 1 | 1992 | 19 | 0.020 |
Why?
|
| Quinazolines | 1 | 1992 | 21 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2012 | 245 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2016 | 881 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2011 | 40 | 0.020 |
Why?
|
| Thrombocytopenia | 1 | 1992 | 59 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2011 | 58 | 0.020 |
Why?
|
| Utrophin | 2 | 2002 | 4 | 0.020 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 1992 | 242 | 0.020 |
Why?
|
| Infant | 1 | 2016 | 1720 | 0.020 |
Why?
|
| Rituximab | 1 | 2011 | 89 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2016 | 2088 | 0.020 |
Why?
|
| Vinblastine | 1 | 2010 | 15 | 0.020 |
Why?
|
| Bleomycin | 1 | 2010 | 35 | 0.020 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 1992 | 235 | 0.020 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2009 | 35 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2016 | 2649 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2011 | 5830 | 0.020 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2012 | 357 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2009 | 241 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2012 | 6953 | 0.020 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1989 | 100 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2009 | 377 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2009 | 579 | 0.020 |
Why?
|
| RNA, Messenger | 2 | 1992 | 1583 | 0.020 |
Why?
|
| Adult | 3 | 2012 | 17567 | 0.020 |
Why?
|
| Child | 1 | 2016 | 4653 | 0.020 |
Why?
|
| Risk Factors | 1 | 2016 | 5471 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2011 | 2496 | 0.010 |
Why?
|
| Adolescent | 1 | 2016 | 6367 | 0.010 |
Why?
|
| Leukemia, Erythroblastic, Acute | 1 | 2000 | 7 | 0.010 |
Why?
|
| Luciferases | 1 | 2000 | 107 | 0.010 |
Why?
|
| Electrophoresis | 1 | 1999 | 16 | 0.010 |
Why?
|
| Chromatography, Affinity | 1 | 1999 | 52 | 0.010 |
Why?
|
| Myeloblastin | 1 | 1999 | 14 | 0.010 |
Why?
|
| Drosophila | 1 | 2002 | 480 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2000 | 503 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 1999 | 709 | 0.010 |
Why?
|
| Neutropenia | 1 | 1997 | 68 | 0.010 |
Why?
|
| Receptors, Calcitriol | 1 | 1995 | 33 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 1995 | 52 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 1995 | 62 | 0.010 |
Why?
|
| Transcription Factor AP-1 | 1 | 1995 | 46 | 0.010 |
Why?
|
| Rats | 1 | 1999 | 2005 | 0.010 |
Why?
|
| Cell Division | 1 | 1995 | 451 | 0.010 |
Why?
|
| Muscle, Skeletal | 1 | 1999 | 789 | 0.010 |
Why?
|
| Ploidies | 1 | 1992 | 4 | 0.010 |
Why?
|
| Cell Aggregation | 1 | 1992 | 21 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 1992 | 152 | 0.010 |
Why?
|
| HeLa Cells | 1 | 1992 | 541 | 0.010 |
Why?
|
| Kinetics | 1 | 1992 | 757 | 0.000 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1997 | 1665 | 0.000 |
Why?
|
| Time Factors | 1 | 1992 | 3778 | 0.000 |
Why?
|